GSK547 manufacturers
- GSK547
-
- $58.00
-
2026-07-27
- CAS:2226735-55-1
- Purity: 99.17%
- Supply Ability: 10g
- GSK547
-
-
2026-07-22
- CAS:2226735-55-1
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1000kg
|
| Product Name: | GSK547 | | Synonyms: | GSK547;RIP1 inhibitor 547;RIP1I;CPD3508;(S)-6-(4-(5-(3,5-Difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperidin-1-yl)pyrimidine-4-carbonitrile;RIP1 inhibitor GSK547;4-Pyrimidinecarbonitrile, 6-[4-[[(5S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]carbonyl]-1-piperidinyl]-;Inhibitor,RIP kinase,inhibit,GSK-547,GSK547,Receptor-interacting protein kinases,RIPK,GSK 547 | | CAS: | 2226735-55-1 | | MF: | C20H18F2N6O | | MW: | 396.39 | | EINECS: | | | Product Categories: | | | Mol File: | 2226735-55-1.mol |  |
| | GSK547 Chemical Properties |
| Boiling point | 578.3±60.0 °C(Predicted) | | density | 1.43±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:65.0(Max Conc. mg/mL);163.98(Max Conc. mM) | | pka | 1.93±0.28(Predicted) | | form | Solid | | color | White to off-white | | InChI | InChI=1S/C20H18F2N6O/c21-15-7-14(8-16(22)9-15)18-1-4-26-28(18)20(29)13-2-5-27(6-3-13)19-10-17(11-23)24-12-25-19/h4,7-10,12-13,18H,1-3,5-6H2/t18-/m0/s1 | | InChIKey | SJVGFKBLUYAEOK-SFHVURJKSA-N | | SMILES | C1=NC(N2CCC(C(N3[C@H](C4=CC(F)=CC(F)=C4)CC=N3)=O)CC2)=CC(C#N)=N1 |
| | GSK547 Usage And Synthesis |
| Uses | GSK547 (GSK'547) is a highly selective and potent inhibitor of receptor-interacting serine/threonine protein kinase 1 (RIPK1), inhibits macrophage-mediated adaptive immune tolerance in pancreatic cancer[1]. | | Biological Activity | GSK'547 is a highly selective and potent inhibitor of RIP1 (RIPK1) with a 400-fold increase in oral exposure compared to GSK'963 in mouse pharmacokinetic studies. | | in vitro | In vitro, treatment with GSK'547 directed bone marrow-derived macrophages to develop an immunogenic phenotype, with up-regulation of MHC-II, TNFa and IFNg expression, and decreased CD206, IL- 10 and TGFb expression. In addition, it also up-regulated STAT1 signaling and decreased STAT3, STAT5 and STAT6 signaling in bone marrow-derived macrophages. Macrophages treated with GSK'547 had stronger ability to capture antigens. | | in vivo | Mice were given GSK'547 through food, the concentration of GSK'547 in vivo was stable within 24 hours, which was higher than the IC50 value in L929 cells. GSK'547 maintained high concentrations in vivo during the 6-week administration. GSK'547 was well tolerated with no obvious pathological features. In mice with in situ pancreatic ductal adenocarcinoma, It reduced tumor burden and prolonged survival compared to control and Nec-1s-treated groups. GSK'547 prevents established tumors and liver metastases. | | target | | Target | Value | RIP1
() | | References | [1] Wang W, et al. RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. Cancer Cell. 2018 Nov 12;34(5):757-774.e7. DOI:10.1016/j.ccell.2018.10.006 |
| | GSK547 Preparation Products And Raw materials |
|
|
Tag:GSK547(2226735-55-1)
Related Product Information
|
|
RET Kinase inhibitor 1
N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide
GSK484
GSK583
GSK369796
GSK461364
GSK-467
GSK481
GSK-3326595
4-Chloro-N-[2-[[5-(trifluoromethyl)-2-pyridinyl]sulfonyl]ethyl]benzamide
GNE 617
|
According to the laws, regulations and policies related to "patent products", the sale of this product is prohibited!
ChemicalBook prompt
The patent owner or licensee of the product has not released any relevant information for the time being.
|